Understand the source comparison
Do Peptides Help With Appetite Suppression: Full Comparison
GLP-1 Agonist (Semaglutide) GLP-1 receptor activation → slowed gastric emptying, extended satiety hormone elevation 14.9% at 68 weeks (STEP-1, 2.4mg weekly) Weekly subcutaneous injection 30–45% during titration (nausea, vomiting, diarrhea) Proven efficacy, man
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GLP-1 Agonist (Semaglutide)
- GLP-1 receptor activation → slowed gastric emptying, extended satiety hormone elevation
- 14.9% at 68 weeks (STEP-1, 2.4mg weekly)
- Weekly subcutaneous injection
- 30–45% during titration (nausea, vomiting, diarrhea)
- Proven efficacy, manageable side effects with slow titration, once-weekly dosing improves adherence
- Dual GLP-1/GIP Agonist (Tirzepatide)
- GLP-1 + GIP receptor activation → enhanced insulin sensitivity, thermogenesis, gastric slowing
- 20.9% at 72 weeks (SURMOUNT-1, 15mg weekly)
- 35–50% during titration (slightly higher than GLP-1-only)
- Highest weight loss efficacy documented to date, dual mechanism addresses both appetite and energy expenditure
- Dual GLP-1/Glucagon Agonist (Mazdutide)
- GLP-1 + glucagon receptor activation → increased energy expenditure, gastric slowing
- 16–18% at 48 weeks (Phase 2 data, dose-dependent)
- 40–55% during titration
- Glucagon component increases thermogenesis but also elevates GI side effects. Promising but tolerance required
- Growth Hormone Secretagogue (MK 677)
- Ghrelin receptor agonism → increased GH/IGF-1, elevated appetite in most users
- No significant weight loss (increases lean mass, not fat loss)
- Daily oral dosing
- Minimal GI effects, increased appetite in 60–70% of users
- Does not suppress appetite. Included for contrast; useful for lean mass retention during deficit but not for appetite control